HR Execs on the Move

Arrakis Therapeutics

www.arrakistx.com

 
Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Patrizio Renzetti
Vice President of Human Resources Profile
Jim Barsoum
Senior Vice President Profile
Michael Gilman
Chairman and Chief Executive Officer Profile

Similar Companies

Momentum for Health

CARF-accredited: Largest private nonprofit agency in Santa Clara County providing mental health services to over 3800 youth, adults and older adults annually.

Boone Drug At New Market

Boone Drug and Healthcare at Deerfield offers a broad range of retail pharmacy, home medical equipment, prosthetic and orthotic goods, home respiratory care, post mastectomy fitters services, enteral therapy services to fill the medical and convalescent

Vanta Bioscience

Vanta Bioscience is a West Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

2nd Chance Treatment Center

Telehealth Available: Trusted Addiction Medicine serving the greater Phoenix, AZ area. Visit our website to book an appointment online: 2nd Chance Treatment Center

OnKure Therapeutics

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.